Page last updated: 2024-09-04

pomalidomide and Myelodysplastic Syndromes

pomalidomide has been researched along with Myelodysplastic Syndromes in 9 studies

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (44.44)	29.6817
2010's	4 (44.44)	24.3611
2020's	1 (11.11)	2.80

Authors

Authors	Studies
Arbab, A; Cotteret, S; Ghez, D; Marzac, C; Saada, V	1
Bassermann, F; Eichner, R; Einsele, H; Fernández-Sáiz, V; Garz, AK; Germing, U; Götze, KS; Haass, C; Heider, M; Jacobs, L; Keller, U; Knop, S; Knorn, AM; Kuster, B; Langer, C; Lemeer, S; Peschel, C; Platzbecker, U; Rudelius, M; Schmid, B; Slawska, J; Targosz, BS; van Bebber, F	1
Krönke, J; Lindner, S	1
Wiernik, PH	1
Gauthier, J; Leleu, X; Wémeau, M; Yakoub-Agha, I	1
Lentzsch, S; Pan, B	1
Knight, R	1
Crane, E; List, A	1
Galili, N; Raza, A	1

Reviews

7 review(s) available for pomalidomide and Myelodysplastic Syndromes

Article	Year
The molecular mechanism of thalidomide analogs in hematologic malignancies. Journal of molecular medicine (Berlin, Germany), 2016, Volume: 94, Issue:12 Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Casein Kinase I; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Interleukin-2; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Peptide Hydrolases; Protein Binding; Proteolysis; Signal Transduction; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination	2016
Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs). Current treatment options in oncology, 2009, Volume: 10, Issue:1-2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Salvage Therapy; Thalidomide; Venous Thromboembolism; Young Adult	2009
[IMiDs in hematology]. Bulletin du cancer, 2011, Volume: 98, Issue:8 Topics: Chronic Disease; Hematologic Neoplasms; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis; Thalidomide; Waldenstrom Macroglobulinemia	2011
The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacology & therapeutics, 2012, Volume: 136, Issue:1 Topics: Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Thalidomide	2012
IMiDs: a novel class of immunomodulators. Seminars in oncology, 2005, Volume: 32, Issue:4 Suppl 5 Topics: Angiogenesis Inhibitors; Clinical Trials, Phase I as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide	2005
Immunomodulatory drugs. Cancer investigation, 2005, Volume: 23, Issue:7 Topics: Humans; Immunosuppressive Agents; Interleukin-12; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Multiple Myeloma; Myelodysplastic Syndromes; Neovascularization, Pathologic; T-Lymphocytes; Thalidomide	2005
Immunomodulatory drugs in myelodysplastic syndromes. Expert opinion on investigational drugs, 2006, Volume: 15, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Animals; Apoptosis; Blood Transfusion; Cell Lineage; Cells, Cultured; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Cytokines; Drug Evaluation, Preclinical; Drugs, Investigational; Erythrocyte Transfusion; Erythropoiesis; Female; Hematopoietic Stem Cells; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; NF-kappa B; Pilot Projects; Thalidomide; Thrombocytopenia; Tumor Necrosis Factor-alpha	2006

Other Studies

2 other study(ies) available for pomalidomide and Myelodysplastic Syndromes

Article	Year
Plasma cell dedifferentiation in refractory multiple myeloma. British journal of haematology, 2021, Volume: 193, Issue:2 Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Dedifferentiation; Dexamethasone; Flow Cytometry; Humans; Immunophenotyping; Male; Multiple Myeloma; Mutation; Myelodysplastic Syndromes; Paraproteinemias; Plasma Cells; Thalidomide; Treatment Failure; Tumor Suppressor Protein p53	2021
Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nature medicine, 2016, Volume: 22, Issue:7 Topics: Adaptor Proteins, Signal Transducing; Basigin; Cell Cycle Proteins; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Oncogene Proteins; Peptide Hydrolases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Teratogenesis; Thalidomide; Ubiquitin-Protein Ligases	2016

Article

Year

Plasma cell dedifferentiation in refractory multiple myeloma.

British journal of haematology, 2021, Volume: 193, Issue:2

Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Dedifferentiation; Dexamethasone; Flow Cytometry; Humans; Immunophenotyping; Male; Multiple Myeloma; Mutation; Myelodysplastic Syndromes; Paraproteinemias; Plasma Cells; Thalidomide; Treatment Failure; Tumor Suppressor Protein p53

2021

Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.

Nature medicine, 2016, Volume: 22, Issue:7

Topics: Adaptor Proteins, Signal Transducing; Basigin; Cell Cycle Proteins; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Oncogene Proteins; Peptide Hydrolases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Teratogenesis; Thalidomide; Ubiquitin-Protein Ligases

2016